IMPORTANCE Neoadjuvant chemotherapy (NAC) followed by radical cystectomy improves survival compared with cystectomy alone for patients with bladder cancer. Although gemcitabine with cisplatin has become a standard NAC regimen, a dose-dense combination of methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) is being adopted at some institutions.
N eoadjuvant chemotherapy (NAC) given before cystectomy is a standard treatment for muscle-invasive bladder cancer, and its use is supported by the findings of numerous randomized clinical trials and metaanalyses, which have found a 6% survival benefit at 10 years. [1] [2] [3] Accordingly, treatment guidelines from a number of organizations, including the American Urological Association/ Society of Urologic Oncology, the National Comprehensive Cancer Network, and the European Association of Urology, recommend NAC as preferred first-line therapy in the management of invasive and advanced disease. [4] [5] [6] However, despite unequivocal evidence supporting its efficacy, the rates of adoption and routine use of NAC have been modest. [7] [8] [9] Various chemotherapy regimens are used in clinical practice; however, most trials examining the efficacy of multiagent NACs have been based on combinations including methotrexate, vinblastine, and cisplatin with or without the addition of an anthracycline (eg, doxorubicin or epirubicin).
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Although a previous landmark trial reported significant improvement in complete pathologic response (38% vs 15%; P < .001) and median overall survival (77 vs 46 months; P = .05) for patients treated with neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy compared with those treated with cystectomy alone, 1 serious toxic effects such as fatigue, nausea, and vomiting were common with MVAC, and more than 50% of patients experienced myelosuppression and mucositis. 13 These adverse events have limited the widespread use of MVAC to date; as a result, the combination of gemcitabine with cisplatin is more commonly used before cystectomy. 14, 15 In the setting of renal insufficiency, the combination of gemcitabine with carboplatin is also used, despite little evidence of its effectiveness. Neoadjuvant phase 2 trial results suggest that dose-dense MVAC (ddMVAC) or accelerated MVAC is well tolerated, safe, and has response rates similar to gemcitabine-cisplatin. [16] [17] [18] Observational studies report similar response rates for neoadjuvant gemcitabine-cisplatin and MVAC. 19, 20 However, few studies comparing cancer control and survival outcomes for NAC regimens exist. The objective of this study was to examine cancer-relevant outcomes across NAC regimens and to determine the relative effectiveness of ddMVAC compared with gemcitabine-cisplatin. Revision and International Statistical Classification of Diseases and Related Health Problems, Tenth Revision diagnosis codes found in administrative data. Chemotherapy agents were identified at the individual patient level and then recoded into regimens annotated with start and finish dates. The most common regimens were gemcitabine-cisplatin, gemcitabine-carboplatin, and ddMVAC. Atypical or uncommon regimens, such as fluorouracil, etoposide, and paclitaxel-based chemotherapy, were categorized as other. Chemotherapy and surgery dates were used to verify neoadjuvant administration. A 6-to 8-week administration period was used to distinguish dose-dense from standard MVAC regimens, and all use of ddMVAC was confirmed with individual medical record reviews. Clinical staging was determined primarily from pathologic findings from transurethral resection of the bladder tumor, supplemented with staging imaging from radiographic studies. Pathologic staging information, including TNM classification, histology, lymph node counts, and surgical margins, was obtained from pathology reports after cystectomy. Disease status, vital status, and duration of follow-up were derived from the HRI's cancer registry death index. Primary outcomes of interest included pathologic downstaging and overall survival, according to NAC regimen. Downstaging was defined as either any decrease in stage or complete pathologic response (TNM classification of pT0N0 or ypT0N0). Overall survival time was measured from date of cystectomy to date of last follow-up or death from any cause.
Methods

Data Sources and Study Population
A control group comprised patients who received surgery alone, so that their downstaging and survival rates could be compared against those of patients receiving NAC. Time to cystectomy was examined as a secondary outcome across NAC groups. In addition, data on adverse events were collected from the subset of patients treated with ddMVAC NAC. For this purpose, toxic effects associated with ddMVAC were abstracted from the medical record and graded according to Common Terminology Criteria for Adverse Events (version 4.0).
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Statistical Analyses
Demographic factors and clinical variables were compared between non-NAC and NAC groups and across NAC regimens. Continuous variables were reported as mean (SD) or median (interquartile range [IQR] ) values. Comparisons were performed using the χ 2 , t, or Wilcoxon rank sum test, as appropriate. Unadjusted and adjusted logistic regression models were used to estimate odds ratios (ORs) and 95% CIs for downstaging, using gemcitabine-cisplatin data as the reference. Multivariable models were adjusted for age, comorbidity, sex, clinical stage, chemotherapy regimen, and number of chemotherapy cycles, with gemcitabine-cisplatin data again used as the reference. Because participants were not randomly assigned to chemotherapy regimens, we also performed propensity score analyses. Logistic regression was used to compute propensity scores to calculate the predictive probabilities of receiving ddMVAC vs gemcitabine-cisplatin. Propensity scores were then included in a second set of logistic regression models to estimate adjusted ORs of any downstaging and pT0N0 for ddMVAC vs gemcitabine-cisplatin.
Kaplan-Meier curves were used to compare overall survival rates and ypT0N0 status among chemotherapy regimens and according to ypT0N0 status. To adjust for confounding factors, we performed multivariable Cox proportional hazards regression modeling and adjusted for age, comorbidity, sex, clinical stage, chemotherapy regimen, and number of cycles. Finally, we calculated a hazard ratio (HR) for ddMVAC vs gemcitabine-cisplatin in our propensity-weighted model for overall survival.
Hypothesis testing was 2-sided, and P < .05 was considered statistically significant. All statistical analyses were performed with SAS statistical software (version 9.4; SAS Institute Inc).
Results
Of the 1113 patients included in the analysis, 861 (77.4%) were male, the median (IQR) age was 67 (60-74) years, and 1051 (94.4%) were white, 27 (2.4%) black, 37 (3.3%) Hispanic/ Latino, and 35 (3.1%) other race/ethnicity. From a registry of 1186 patients who underwent cystectomies at the Moffitt Cancer Center from January 1, 2007, to May 31, 2017, 1113 patients were included in the analyses (Figure 1) ddMVAC indicates dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin; GC, gemcitabine-cisplatin; and NAC, neoadjuvant chemotherapy. a P = .02 for pT0N0 downstaging and P = .10 for any downstaging. (Figure 2) . A pairwise comparison of gemcitabine-cisplatin and ddMVAC significantly favored ddMVAC (χ 2 = 5.20; P = .02). The pT0N0 rate for gemcitabinecarboplatin was 9.4%, and for cystectomy without NAC, it was 10.7%. Dose-dense MVAC was also associated with a significantly higher likelihood of complete pathologic response in adjusted multivariable logistic regression models (OR, 2.67; 95% CI, 1.50-4.77) and in a separate propensity-weighted model comparing gemcitabine-cisplatin with ddMVAC (OR, 1.52; 95% CI, 0.99-2.35; P = .05) ( Table 2) . Unadjusted and adjusted survival analyses demonstrated a higher median overall survival among patients treated with neoadjuvant ddMVAC compared with those treated with other chemotherapy regimens. Two-year Kaplan-Meier survival probability estimates were 73.3% (95% CI, 48.0%-89.1%) for ddMVAC, 62% (95% CI, 53.4%-69.9%) for gemcitabine-cisplatin, and 34.8% (95% CI, 18.8%-55.1%) for gemcitabine-carboplatin (log-rank P = .002; Figure 3A ). Achieving ypT0N0 was also a significant predictor of overall survival, regardless of chemotherapy type (log-rank P < .001; Figure 3B ). The estimated risk of death was 60% lower for ddMVAC than for gemcitabine-cisplatin, according to adjusted (HR, 0.42; 95% CI, 0.17-1.06; P = .07) and propensityweighted modeling (HR, 0.44; 95% CI, 0.14-1.38; P = .16) ( Table 2 ), but these did not reach statistical significance. In contrast, the adjusted risk of death for gemcitabine-carboplatin was twice that of gemcitabine-cisplatin (HR, 2.00; 95% CI, 1.16-3.44; P = .01). The full Cox proportional hazard model for overall survival results are reported in eTable 3 in the Supplement. Seventy-eight patients with ypT0N0 (92.8%) were alive 2 years after surgery. When patients with ypT0N0 were stratified by NAC regime, 46 (92.0%) receiving gemcitabinecisplatin, 3 (100%) receiving gemcitabine-carboplatin, 19 (100%) receiving ddMVAC, and 10 (83.3%) receiving other types of NAC were alive at 2 years.
The median (IQR) treatment time for ddMVAC was 35 (28-46) days (mean [SD] treatment time, 40.5 [17.0] days). The summary of ddMVAC adverse events (eTable 2 in the Supplement) shows that the most common grade 1 or 2 event was fatigue (n = 26) and that the most common grade 3 event was anemia requiring blood transfusion (n = 3). No grade 4 adverse events were identified. These results are consistent with previously published toxic effect reports for ddMVAC.
16,18 Dosedense MVAC also hastened readiness for surgery. The times from start of NAC to cystectomy were 95 days for ddMVAC, 119 days for gemcitabine-cisplatin, and 134 days for gemcitabinecarboplatin ( Figure 3C ; χ 2 = 25.1; P < .001).
Discussion
Cisplatin-based chemotherapy administered before cystectomy improves survival among patients with muscle-invasive bladder cancer compared with treatment with cystectomy Our comparative analyses identified a significantly higher likelihood of ypT0N0 and longer survival intervals for patients who received ddMVAC compared with those treated with other regimens. We observed a complete response rate of 41.3% for patients who received an average of 3.3 cycles of ddMVAC, which was significantly higher than the rate of 24.6% for those who received an average of 3.7 cycles of gemcitabine-cisplatin. Patients treated with ddMVAC also had higher survival rates than those treated with other regimens, and although the survival association did not reach statistical significance, the magnitude of the advantage is relatively large (HR, 0.42; 95% CI, 0.17-1.06). We also confirmed a surrogate association of ypT0N0 disease status after therapy with overall survival. The association of complete pathologic response with survival for patients with nonmetastatic bladder cancer treated with chemotherapy and cystectomy has been documented in previous studies.
23,29,30
Another important finding of the present study was that neoadjuvant gemcitabine-carboplatin appears essentially ineffective. Complete response rates were low (9.4%), and more concerning still, the adjusted risk of death was significantly higher than for the reference gemcitabine-cisplatin group (HR, 2.0; 95% CI, 1.19-3.38). These results raise questions regarding the role of neoadjuvant gemcitabine-carboplatin. Finally, we confirmed that the time from start of NAC to cystectomy was expedited with ddMVAC, allowing patients to complete their global treatment more quickly than with other NAC regimens.
31
Reported ypT0N0 rates associated with standard neoadjuvant MVAC range from 22% to 29% in observational studies 19, 20, 32 and from 34% to 38% in prospective randomized clinical trials. complete response rates reported in previous observational studies may be a function of differences in tolerance and duration of chemotherapy. This type of clinical and treatment information may not be readily available or examined in multisite observational studies that are based on shared data, further limiting insight regarding lower-than-expected complete pathologic response rates.
20,32,34
Limitations A number of limitations warrant discussion. These include the nonrandomized retrospective design, which could result in bias and confounding. In addition to using standard adjustment methods, we included propensity-score weights to account for measured differences between patients. Propensity scores attempt to account for baseline characteristics that may influence assignment to treatment groups and allow for inclusion of multiple, measurable covariates without overfitting the regression model. The weighted combination of covariates contributes to a single propensity score applied across treatment groups to "level the playing field" before hypothesis testing.
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Unmeasured differences in patient groups could lead to residual confounding, which is a limitation in all observational comparative studies. For example, although we did control for comorbidity based on the Elixhauser method, 21 there may be unmeasured factors influencing frailty or performance status that are not included in multivariable or propensityweighted models. In addition, our study does not account for patients who received NAC and did not have surgery owing to complications or symptomatic adverse events or disease progression. The relatively small size of the ddMVAC group in our sample is a limitation, which may have lessened our statistical power. Although our adjusted analyses failed to reach a .05 significance threshold, the magnitude of the survival differences that we observed were substantial and suggest the clinical importance of the findings. With additional follow-up and a larger ddMVAC sample, the CIs around the adjusted and propensity-weighted hazard estimates will likely tighten. Furthermore, we were able to demonstrate a direct and significant relationship between ypT0N0 downstaging and survival, adding plausibility to the survival benefit of ddMVAC compared with gemcitabine-cisplatin. These limitations notwithstanding, our study findings contribute substantively to the evidence around neoadjuvant ddMVAC.
Conclusions
Our data suggest that neoadjuvant ddMVAC followed by radical cystectomy is associated with higher complete response rates and disease control than gemcitabinecisplatin and that the pT0 rate after treatment with neoadjuvant gemcitabine-carboplatin is no different than that achieved with cystectomy alone. We also found that ddMVAC was associated with longer survival intervals and a lower risk of death than the other treatments examined, although those findings did not reach statistical significance, indicating that larger comparative studies are needed to definitively answer questions regarding survival. 
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